Cerebral	cerebral	O	DISEASE	OTHERS	I
hemorrhage	hemorrhage	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
phenylpropanolamine	phenylpropanolamine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
caffeine	caffeine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Phenylpropanolamine	phenylpropanolamine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
PPA	ppa	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
drug	drug	O	O	O	O
that	that	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
serious	serious	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
including	including	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
.	.	O	O	O	O

It	it	O	O	O	O
is	is	O	O	O	O
often	often	O	O	O	O
combined	combined	O	O	O	O
with	with	O	O	O	O
caffeine	caffeine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
diet	diet	O	O	O	O
preparations	preparations	O	O	O	O
and	and	O	O	O	O
"	"	O	O	O	O
look-alike	look-alike	O	O	O	O
"	"	O	O	O	O
pills	pills	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
order	order	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
if	if	O	O	O	O
PPA/caffeine	ppa/caffeine	O	O	O	O
can	can	O	O	O	O
lead	lead	O	O	OTHERS	I
to	to	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
in	in	O	O	O	O
normotensive	normotensive	O	O	O	O
and/or	and/or	O	O	O	O
hypertensive	hypertensive	O	DISEASE	OTHERS	I
rats	rats	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
administered	administered	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
in	in	O	O	O	O
six	six	O	O	O	O
times	times	O	O	O	O
the	the	O	O	O	O
allowed	allowed	O	O	O	O
human	human	O	O	O	O
dose	dose	O	O	O	O
calculated	calculated	O	O	O	O
on	on	O	O	O	O
a	a	O	O	O	O
per	per	O	O	O	O
weight	weight	O	O	O	O
basis	basis	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
rats	rats	O	O	O	O
two	two	O	O	O	O
times	times	O	O	O	O
per	per	O	O	O	O
day	day	O	O	O	O
for	for	O	O	O	O
five	five	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

Subarachnoid	subarachnoid	O	O	O	O
and	and	O	O	O	O
cerebral	cerebral	O	DISEASE	OTHERS	I
hemorrhage	hemorrhage	O	DISEASE	OTHERS	I
was	was	O	O	O	O
noted	noted	O	O	O	O
in	in	O	O	O	O
18	18	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
hypertensive	hypertensive	O	DISEASE	OTHERS	I
rats	rats	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
single	single	O	O	O	O
PPA/caffeine	ppa/caffeine	O	O	O	O
administration	administration	O	O	O	O
(	(	O	O	O	O
same	same	O	O	O	O
dose	dose	O	O	O	O
)	)	O	O	O	O
lead	lead	O	O	OTHERS	I
to	to	O	O	O	O
acute	acute	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
in	in	O	O	O	O
both	both	O	O	O	O
the	the	O	O	O	O
normotensive	normotensive	O	O	O	O
and	and	O	O	O	O
hypertensive	hypertensive	O	DISEASE	OTHERS	I
animals	animals	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
PPA/caffeine	ppa/caffeine	O	O	O	O
can	can	O	O	O	O
lead	lead	O	O	OTHERS	I
to	to	O	O	O	O
cerebral	cerebral	O	DISEASE	OTHERS	I
hemorrhage	hemorrhage	O	DISEASE	OTHERS	I
in	in	O	O	O	O
previously	previously	O	O	O	O
hypertensive	hypertensive	O	DISEASE	OTHERS	I
animals	animals	O	O	O	O
when	when	O	O	O	O
administered	administered	O	O	O	O
in	in	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
allowed	allowed	O	O	O	O
dosage	dosage	O	O	O	O
.	.	O	O	O	O

An	an	O	O	O	O
acute	acute	O	O	O	O
elevation	elevation	O	O	O	O
in	in	O	O	O	O
blood	blood	O	O	O	O
pressure	pressure	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
contributing	contributing	O	O	O	O
factor	factor	O	O	O	O
.	.	O	O	O	O

